BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioXcel Therapeutics reports FDA approval milestone and financial resilience

BioXcel Therapeutics showcased strong financials with a net revenue of $238,000 and a net loss of $54.8 million, underpinned by a solid cash position of $193.7 million.
The FDA approval of IGALMI and upcoming clinical data announcements demonstrate progress in drug development and commercialization efforts.
While facing challenges such as slow product uptake and operating cost uncertainties, BioXcel has opportunities to drive market penetration through strategic initiatives.
The company's strengths lie in its innovative AI platform, strong cash reserves, and proactive approach to advancing its pipeline and commercialization strategies.

BioXcel Therapeutics reports Q1 progress, eyes revenue growth opportunities

BioXcel Therapeutics showcased strong commercial and clinical progress in Q1 2023 earnings call.
While facing challenges in dose selection and strategic options, the company remains optimistic about revenue growth.
Opportunities lie in maintaining commercial metrics, advancing clinical pipeline, and leveraging FDA-approved products.

BioXcel Therapeutics reports Q2 results, refocuses strategy for growth

BioXcel Therapeutics navigated challenges from investigator misconduct by refocusing on key therapeutic areas and strategic partnerships for financial stability.
Despite workforce reductions and operational changes, the company remains committed to advancing treatments for neurological disorders and sharing progress transparently.
Ongoing FDA discussions, positive trial results, and strategic reprioritization position BioXcel Therapeutics for potential growth and regulatory milestones.

BioXcel Therapeutics advances clinical programs and secures financial backing

BioXcel Therapeutics showcased progress in clinical programs and financial flexibility, with a focus on Alzheimer's-related opportunities.
Challenges include ongoing safety discussions, cash burn rate management, and logistical complexities in home setting trials.
Opportunities lie in targeting underserved markets, regulatory support, economic alleviation for hospitals, and efficient program advancement.
Balancing financial strategies and ensuring data integrity and regulatory alignment are key priorities for BioXcel's future success.

BioXcel Therapeutics reports strong Q4 results and advances clinical programs

BioXcel Therapeutics showcased positive financial performance and progress in late-stage clinical programs, indicating a promising outlook for the company's future.
While facing challenges such as trial timing reevaluation and funding uncertainties, the company's proactive approach and strategic focus present opportunities for growth and innovation.
By leveraging its strengths in program development and financial planning, BioXcel Therapeutics can navigate challenges and capitalize on opportunities to drive value for stakeholders.

BioXcel Therapeutics reports robust Q1 performance and advances late-stage programs

BioXcel Therapeutics demonstrated strong financial performance in Q1 2024, with notable revenue growth and reduced net losses. The company's focus on expanding market potential, advancing late-stage programs, and strengthening intellectual property positions it well for future growth. Challenges include sustaining commercialization success and managing expenses effectively.

BioXcel Therapeutics excels in Q2 with strong financial and clinical performance

BioXcel Therapeutics demonstrated strong financial and clinical performance in Q2 2024, with revenue growth, reduced expenses, and promising outcomes in key programs.
The company's strategic focus on expanding into home settings, addressing unmet needs, and exploring innovative therapies positions it well for sustained growth and value creation.
While facing challenges in execution and financial management, BioXcel Therapeutics has opportunities to leverage its strengths, drive innovation, and establish market leadership in mental health treatment.

BioXcel Therapeutics advances pivotal trials amidst financial challenges

BioXcel Therapeutics made notable progress in its clinical trials and received positive feedback from the FDA, indicating a strong focus on innovation and regulatory compliance.
While facing financial challenges with a net loss in Q3 2024, the company demonstrated cost management efforts through reduced expenses.
The company's ability to secure grants and maintain a healthy cash position positions it well to capitalize on opportunities for growth and development in the mental health therapeutics market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

NEW YORK , Aug. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the "Class Period"), of the important September 5, 2023 lead plaintiff deadline. SO WHAT: If you purchased BioXcel Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc. (“BioXcel”) (NASDAQ: BTAI). The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a.

BioXcel Therapeutics, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BTAI Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

NEW YORK, NY / ACCESSWIRE / August 21, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ:BTAI) between December 15, 2021 and June 28, 2023. If you suffered a loss, contact us at the link below.

BTAI LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioXcel Therapeutics, Inc.

NEW YORK , Aug. 19, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in BioXcel stock or options between December 15, 2021 and June 28, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

BIOXCEL SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options

NEW ORLEANS , Aug. 18, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 5, 2023 to file lead plaintiff applications in a securities class action lawsuit against BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company's securities between December 15, 2021 and June 28, 2023, inclusive (the "Class Period").

BIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the "Class Period"), of the important September 5, 2023 lead plaintiff deadline. SO WHAT: If you purchased BioXcel Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

RADNOR, Pa. , Aug. 17, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut against BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI).

Securities Class Action Reminder for (BTAI) Investors: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioXcel investors who were adversely affected by alleged securities fraud between December 15, 2021 and June 28, 2023.

BTAI LAWSUIT ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

The biotech takes another hit following its earnings release on Monday. Several analysts became notably more bullish on its prospects.

Why BioXcel Therapeutics Stock Flopped Again Today

NEW YORK , Aug. 15, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) alleging that the Company violated federal securities laws. Class Period: December 15, 2021 to June 28, 2023 Lead Plaintiff Deadline: September 5, 2023 No obligation or cost to you.

BTAI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc. Shareholders

OAKLAND, Calif.--(BUSINESS WIRE)---- $BTAI #BTAI--Gibbs Law Group reminds investors that a class action lawsuit has been filed against BioXcel Therapeutics, Inc. (NASDAQ: BTAI).

Lost Money in BioXcel Therapeutics, Inc? Gibbs Law Group Investigates Potential Securities Law Violations

MannKind

Novavax

Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common for firms that engage in the development of pharmaceuticals.

3 Biotech Stocks to Sell in August Before They Crash and Burn

BioXcel announced Q2 results and a major strategic shift this morning. The biotech specialist has halted plans for Phase 2 clinical trials that were important to the bull thesis on its stock.

Why BioXcel Therapeutics Stock Is Getting Crushed Today

BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Vimal Mehta - Founder & CEO Richard Steinhart - SVP & CFO Matt Wiley - SVP & Chief Commercial Officer Robert Risinger - Chief Medical Officer, Neuroscience Frank Yocca - Chief Scientific Officer Conference Call Participants Gregory Harrison - Bank of America Colin Bristow - UBS Sumant Kulkarni - Canaccord Raghuram Selvaraju - H.C. Wainwright Yatin Suneja - Guggenheim Securities Samir Devani - Rx Securities Kambiz Yazdi - Jefferies Operator Good morning, and welcome to BioXcel Therapeutics' Second Quarter 2023 Financial Results Conference Call.

BioXcel Therapeutics, Inc. (BTAI) Q2 2023 Earnings Call Transcript

BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Monday after the biopharmaceutical company announced layoffs. This has BioXcel Therapeutics cutting over 50% of its workforce.

Why Is BioXcel Therapeutics (BTAI) Stock Down 46% Today?

BioXcel Therapeutics Inc  (NASDAQ:BTAI) is plummeting, last seen down 46.3% to trade at $3.98 after its second-quarter earnings report.

Biotech Stock Plummets After Halving Workforce

BioXcel Therapeutics Inc (NASDAQ:BTAI) stock opened close to 45% lower as trading kicked off in New York on Monday after it revealed it would be wielding the axe across its business. Around half of BioXcel's workforce is to be laid off whilst it cuts operations and focusses down solely on its most advance treatment line only.

BioXcel Therapeutics stock plummets as it cuts jobs in half to focus on AI-powered innovation

Allogene Therapeutics Inc

Stocks that are heavily shorted have the potential to skyrocket as traders are forced to cover their short positions by buying back the stock. This can be an extremely profitable strategy if you find the right stock at the right time.

Short squeeze alert for August 14th: Two stocks poised for lift-off

Shares of BioXcel Therapeutics BTAI, +0.14% tumbled 27% premarket on Monday as the biopharma company said it would cut its workforce by about 58%. BioXcel, which uses artificial intelligence to develop medicines, also said it is looking to reduce more than 50% of its cash burn, to about $80 million annually going forward.

BioXcel Therapeutics to cut workforce 58%, stock falls 27%

BioXcel Therapeutics Inc said on Monday it will reduce its workforce to 80 employees from about 190, as the drugmaker shifts its focus to treatments for agitation.

BioXcel announces job cuts to focus on agitation related treatment

B usiness to prioritize high- potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer's disease

BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

NEW YORK , Aug. 14, 2023 /PRNewswire/ -- Attention BioXcel Therapeutics, Inc. ("BioXcel") (NASDAQ: BTAI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between December 15, 2021 and June 28, 2023. If you suffered a loss on your investment in BioXcel, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind BioXcel Investors of a Lead Plaintiff Deadline of September 5, 2023

NEW YORK , Aug. 11, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the "Class Period"), of the important September 5, 2023 lead plaintiff deadline. SO WHAT: If you purchased BioXcel Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAI

NEW YORK , Aug. 11, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/bioxcel-class-action-loss-submission-form/?id=43310&from=4 The lawsuit seeks to recover losses for shareholders who purchased BioXcel between December 15, 2021 and June 28, 2023.

BTAI SHAREHOLDER ALERT: Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023

CEDARHURST, N.Y. , Aug. 9, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of BioXcel Therapeutics, Inc. (NasdaqCM: BTAI), if they purchased the Company's securities between December 15, 2021 and June 28, 2023, inclusive (the "Class Period").

News for BioXcel Therapeutics Stock (BTAI)